Transdermal CBD Gel for SYNGAP1 Seizures Without Sedation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a treatment of SYNGAP1 encephalopathy symptoms such as seizures and behavioral problems that does not produce unwanted side effects like somnolence, lethargy, or exacerbate behavioral issues, as existing oral CBD treatments have adverse effects and limited efficacy.
Innovation Solution
Transdermal administration of cannabidiol (CBD) to treat SYNGAP1 encephalopathy, including behavioral problems and seizures, using a permeation-enhanced gel formulation to avoid gastrointestinal and liver-related adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral CBD is administered to treat SYNGAP1 encephalopathy, then seizures and behavioral problems are treated, but gastrointestinal adverse events and psychoactive effects occur
Solution Approach 1:
The patent uses a transdermal delivery system as an intermediary between CBD and the body's internal systems. The gel formulation applied to the skin serves as a mediator that allows CBD to enter the bloodstream through the dermal layer, bypassing the gastrointestinal tract entirely. This resolves the contradiction by maintaining treatment efficacy while eliminating GI adverse events through an alternative delivery pathway.
Solution Approach 2:
The patent replaces the oral mechanical delivery system (ingestion through GI tract) with a transdermal delivery system. Instead of swallowing CBD capsules or solution that must pass through the digestive system, the medication is delivered through the skin using a gel formulation that penetrates the dermal layer directly into circulation, substituting one delivery mechanism for another that avoids the harmful GI pathway.
2Reliability
If oral CBD is administered to treat SYNGAP1 encephalopathy, then seizures and behavioral problems are treated, but somnolence and sedation occur
Solution Approach 1:
The transdermal gel acts as an intermediary delivery system that provides controlled, steady-state absorption of CBD through the skin. This gradual release mechanism avoids the rapid peak concentrations achieved through oral administration, thereby maintaining therapeutic efficacy while reducing the intensity of sedative side effects like somnolence and excessive drowsiness.
3Reliability
If oral CBD is administered to treat SYNGAP1 encephalopathy, then seizures and behavioral problems are treated, but CBD degrades into THC causing psychoactive effects
Solution Approach 1:
The transdermal delivery system serves as a protective intermediary that delivers CBD directly to the bloodstream without exposure to gastric acid. The gel formulation and dermal absorption pathway prevent the chemical degradation that occurs in the stomach, thereby maintaining CBD's chemical integrity and preventing its conversion to psychoactive THC.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Transdermal CBD reduces SYNGAP1 seizures by up to 73% and improves behavioral problems, enhancing daily satisfaction and well-being, while minimizing side effects like somnolence.
Implementation Method 1
transdermally administering an effective amount of cannabidiol (CBD) to the subject
Implementation Method 2
transdermal administration of cannabidiol (CBD) to treat SYNGAP1 encephalopathy, including behavioral problems and seizures, using a permeation-enhanced gel formulation
Data Source
AI summary
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.